rxpertusa logo spacer rxpertusa wings
logo spacer spacer spacer
rxpertusa
spacer home
about us
assessment tools
sample consult
contact us

red line

spacer spacer news

The latest Mainline newsletters for the General Public are listed here.


news

For healthcare professionals we have a Mainline newsletter in a Professional version here.


Printer Friendly

Mainline

Volume 2 December 2, 2005 Number 12

An Exclusive Continuing Education Publication of Acadiana Consultant Pharmacy Service
Author, Publisher, Editor-in Chief, Typesetter & Printer, Charles S. Feucht,PD,FASCP PharmD candidate

Medication News & Update

Second Generation Antidepressant Agents Compared:

 

    A recent article appearing in the Annals of Internal Medicine indicates that there appears to be little difference in efficacy with respect to treating major depressive disorders in this group of agents. The agents compared were six SSRI agnets, buproprion, duloxetine, mirtazapine and venlafaxine.

The article indicated that approximately 96% of the studies in head – to – head trials done by the researchers at the University of North Carolina Chapel Hill (46  randomized controlled trials  and 21 observational studies) to compare efficacy and tolerability had at least 1 author affiliated with a pharmaceutical company.

The end result was only minimal differences were noted in efficacy. Based on this information the clinician should make the selection of the agent based on side effect profile, approved indications, cost considerations and formulary restrictions.

For more information see the article in Annals of Intenal Medicine 2005; 143:415-426.

spacer

rule

Home ] [ About Us  ] [ Assessment Tools  ] [ Sample Consult  ]
Contact Us  ]

Copyright © www.rxpertusa.com. Designed by PcHousekeeping.com
  spacer spacer